heart failure | pharmaphorum

Wednesday 16 September 2026

heart failure

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

News

ESC26: AZ's relaxin agonist shows promise in heart failure

ESC26: AZ's relaxin agonist shows promise in heart failure

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.

News

ESC26: Heart attack reclassification rights gender imbalance

ESC26: Heart attack reclassification rights gender imbalance

New definitions of myocardial infarction released at ESC 2026 recognise that there are different causes - and could lead to better treatment of women.

News

Tenax trounced by phase 3 heart failure readout

Tenax trounced by phase 3 heart failure readout

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

News

Bayer building in Reading

Bayer's Kerendia on course for NHS use in heart failure

Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.

News

Novo Nordisk microRNA drug fluffs its lines in heart failure

Novo Nordisk microRNA drug fluffs its lines in heart failure

A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.